CLASS II Drug recall · Reported 17 Jun 2020 · FDA Enforcement Report

Ketorolac Tromethamine Injection, USP, 60 mg per (30 mg per mL) recalled

Fresenius Kabi USA is recalling Ketorolac Tromethamine Injection, USP, 60 mg per (30 mg per mL), distributed nationwide in the US. The recall was initiated on 20 Apr 2020 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: 6119229, 6119273, Exp 06/2020; 6119843, Exp 09/2020; 6121115, Exp 02/2021; 6121451, 6121452, 6121496, Exp 03/2021
NDC63323-161, 63323-162
UPC0363323162115, 0363323161002, 0363323162009, 0363323162030
Quantity recalled3,497,575 vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1297-2020
FDA event ID
85504
Recalling firm
Fresenius Kabi USA, Lake Zurich, IL
Manufacturer
Fresenius Kabi USA, LLC
Classification
Class II
Status
Terminated
Recall initiated
20 Apr 2020
FDA classified
8 Jun 2020
Reported
17 Jun 2020
Type
Voluntary: Firm initiated
Customers notified by
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Reason category
Particulate Matter
Drug class
Pain Medication

Timeline

20 Apr 2020Recall initiated by company
8 Jun 2020Classified by FDA+49 days
17 Jun 2020Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Presence of Particulate Matter - found in reserve sample vials at the firm.

Product as listed by the FDA

Ketorolac Tromethamine Injection, USP, 60 mg per 2 mL (30 mg per mL), packaged in 2 mL Single Dose Vials (NDC 63323-162-03), 25 x 2 mL Single Dose Vials per tray (NDC 63323-162-02); For IM use only, Not for IV use, Rx only, Fresenius Kabi, Lake Zurich, IL 60047.

Where it was distributed

USA Nationwide and Puerto Rico

Nationwide Puerto Rico

Questions about this recall

Is Ketorolac Tromethamine Injection, USP, 60 mg per (30 mg per mL) recalled?

Yes. Fresenius Kabi USA recalled Ketorolac Tromethamine Injection, USP, 60 mg per (30 mg per mL) on 20 Apr 2020. The recall is Class II and its status is Terminated. Recall number D-1297-2020.

Why was it recalled?

Presence of Particulate Matter - found in reserve sample vials at the firm.

Which lots are affected?

Lot #: 6119229, 6119273, Exp 06/2020; 6119843, Exp 09/2020; 6121115, Exp 02/2021; 6121451, 6121452, 6121496, Exp 03/2021

Where was it sold?

USA Nationwide and Puerto Rico

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Fresenius Kabi USA

All 94

Other Ketorolac Tromethamine recalls

All 19
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIKetorolac Tromethamine Injection, USP, 60 mg recalled by Aspiro PharmaKetorolac TromethamineAspiro PharmaParticulate MatterNationwide
DrugCLASS IIKetorolac Tromethamine Ophthalmic Solution recalled by ApotexKetorolac TromethamineApotexSterilityNationwide
DrugCLASS IIKetorolac Tromethamine Ophthalmic Solution recalled by ApotexKetorolac TromethamineApotexSterilityNationwide
DrugCLASS IIKetorolac Tromethamine Injection, USP 60 mg/ (30 mg/mL) recalledKetorolac TromethamineNephron ScManufacturing (CGMP) DeviationsNationwide
DrugCLASS IKetorolac Tromethamine Injection, USP, 30 mg per mL recalledKetorolac TromethamineFresenius Kabi USAParticulate MatterNationwide